Advertisement
Advertisement
DNTH
Dianthus Therapeutics, Inc. Common Stock
92.25
USDSponsored
+4.72
+5.39%
Jun 24, 11:26 UTC -4
Open
DNTH Earnings Reports
Positive Surprise Ratio
DNTH beat 22 of 32 last estimates.
69%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$301.15K
/-$0.88
Implied change from Q1 26 (Revenue/ EPS)
-34.96%
/+3.53%
Implied change from Q2 25 (Revenue/ EPS)
+56.04%
/--
Dianthus Therapeutics, Inc. Common Stock earnings per share and revenue
On May 05, 2026, DNTH reported earnings of -0.85 USD per share (EPS) for Q1 26, beating the estimate of -1.09 USD, resulting in a 22.28% surprise. Revenue reached 463.00 thousand, compared to an expected 361.29 thousand, with a 28.15% difference. The market reacted with a +0.20% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.88 USD, with revenue projected to reach 301.15 thousand USD, implying an increase of 3.53% EPS, and decrease of -34.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Dianthus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Dianthus Therapeutics, Inc. Common Stock reported EPS of -$0.85, beating estimates by 22.28%, and revenue of $463.00K, 28.15% above expectations.
How did the market react to Dianthus Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 0.2%, changed from $90.24 before the earnings release to $90.42 the day after.
When is Dianthus Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Dianthus Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Dianthus Therapeutics, Inc. Common Stock is expected to report EPS of -$0.88 and revenue of $301.15K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement